JP2012512151A - Ｔｒｐｖ３モジュレーターとしての縮合イミダゾールカルボキサミド - Google Patents

Ｔｒｐｖ３モジュレーターとしての縮合イミダゾールカルボキサミド Download PDF

Info

Publication number
JP2012512151A
JP2012512151A JP2011540235A JP2011540235A JP2012512151A JP 2012512151 A JP2012512151 A JP 2012512151A JP 2011540235 A JP2011540235 A JP 2011540235A JP 2011540235 A JP2011540235 A JP 2011540235A JP 2012512151 A JP2012512151 A JP 2012512151A
Authority
JP
Japan
Prior art keywords
imidazo
vinyl
thiazole
carboxamide
thiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011540235A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012512151A5 (cg-RX-API-DMAC7.html
Inventor
サチン サナーラル チョードリー，
アブラハム トーマス，
アショク バーウサヘブ カダム，
サチン バサントラオ ドーン，
スレシュ マハデブ カダム，
ニーリマ カーイラトカール−ジョシ，
ビジャ ガナパティ カッティージ，
Original Assignee
グレンマーク ファーマシューティカルズ， エセ．アー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グレンマーク ファーマシューティカルズ， エセ．アー． filed Critical グレンマーク ファーマシューティカルズ， エセ．アー．
Publication of JP2012512151A publication Critical patent/JP2012512151A/ja
Publication of JP2012512151A5 publication Critical patent/JP2012512151A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011540235A 2008-12-15 2009-12-15 Ｔｒｐｖ３モジュレーターとしての縮合イミダゾールカルボキサミド Pending JP2012512151A (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
IN2610/MUM/2008 2008-12-15
IN2610MU2008 2008-12-15
US14113308P 2008-12-29 2008-12-29
US61/141,133 2008-12-29
IN145/MUM/2009 2009-01-22
IN145MU2009 2009-01-22
US15024809P 2009-02-05 2009-02-05
US61/150,248 2009-02-05
IN1397/MUM/2009 2009-06-10
IN1397MU2009 2009-06-10
US22161509P 2009-06-30 2009-06-30
US61/221,615 2009-06-30
IN1730MU2009 2009-07-29
IN1730/MUM/09 2009-07-29
US23745609P 2009-08-27 2009-08-27
US61/237,456 2009-08-27
PCT/IB2009/007951 WO2010070452A1 (en) 2008-12-15 2009-12-15 Fused imidazole carboxamides as trpv3 modulators

Publications (2)

Publication Number Publication Date
JP2012512151A true JP2012512151A (ja) 2012-05-31
JP2012512151A5 JP2012512151A5 (cg-RX-API-DMAC7.html) 2013-02-14

Family

ID=42241253

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011540235A Pending JP2012512151A (ja) 2008-12-15 2009-12-15 Ｔｒｐｖ３モジュレーターとしての縮合イミダゾールカルボキサミド

Country Status (12)

Country Link
US (1) US8318928B2 (cg-RX-API-DMAC7.html)
EP (1) EP2367825A1 (cg-RX-API-DMAC7.html)
JP (1) JP2012512151A (cg-RX-API-DMAC7.html)
AR (1) AR076830A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009329192A1 (cg-RX-API-DMAC7.html)
CA (1) CA2746077A1 (cg-RX-API-DMAC7.html)
EA (1) EA201190004A1 (cg-RX-API-DMAC7.html)
GE (1) GEP20146099B (cg-RX-API-DMAC7.html)
MX (1) MX2011006132A (cg-RX-API-DMAC7.html)
NZ (1) NZ595777A (cg-RX-API-DMAC7.html)
TW (1) TW201022283A (cg-RX-API-DMAC7.html)
WO (1) WO2010070452A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020502089A (ja) * 2016-12-09 2020-01-23 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 化合物、組成物および方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010073128A2 (en) * 2008-12-26 2010-07-01 Glenmark Pharmaceuticals, S.A. Fused imidazole derivatives as trpv3 antagonist
JP2013538800A (ja) * 2010-08-10 2013-10-17 アッヴィ・インコーポレイテッド 新規ｔｒｐｖ３モジュレーター
WO2012072512A1 (en) * 2010-11-29 2012-06-07 Glaxo Group Limited N-cyclobutyl-imidazopyridine or -pyrazolopyridine carboxamides as trpv1 antagonists
KR101834362B1 (ko) 2011-03-18 2018-03-05 바이엘 인텔렉쳐 프로퍼티 게엠베하 N-(3-카바모일페닐)-1h-피라졸-5-카복사미드 유도체 및 동물 해충을 구제하기 위한 그의 용도
WO2012129491A1 (en) 2011-03-24 2012-09-27 Abbott Laboratories Trpv3 modulators
US8754101B2 (en) 2011-04-11 2014-06-17 Glaxo Group Limited N-cyclobutyl-imidazopyridine-methylamine as TRPV1 antagonists
CA2853097A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Novel trpv3 modulators
CN104718213B (zh) * 2012-07-18 2018-02-27 圣母大学 5,5‑杂芳族抗感染化合物
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
CN118702672A (zh) 2020-01-29 2024-09-27 卡玛瑞制药有限公司 用于治疗皮肤病症的化合物和组合物
TW202146393A (zh) 2020-03-03 2021-12-16 美商皮克醫療公司 Eif4e抑制劑及其用途
CN118103368A (zh) 2021-08-25 2024-05-28 皮克医疗公司 Eif4e抑制剂及其用途
JP2024532276A (ja) 2021-08-25 2024-09-05 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02104578A (ja) * 1988-08-25 1990-04-17 Fujisawa Pharmaceut Co Ltd ベンズアゾール誘導体、その製造法およびそれを含有する医薬組成物
JP2009514954A (ja) * 2005-11-04 2009-04-09 ハイドラ バイオサイエンシズ インコーポレイテッド Ｔｒｐｖ３機能を変調するための化合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444770A (en) * 1980-05-29 1984-04-24 Bayer Aktiengesellschaft New imidazoazole-alkenoic acid amide compounds, intermediate products for their production, their production, and their medicinal use
US5204352A (en) * 1987-09-29 1993-04-20 The United States Of America As Represented By The Secretary Of The Army Compounds exhibiting anti-parasitic activity and a method for their use
JPH02105085A (ja) 1988-10-14 1990-04-17 Komatsu Ltd 磁気センサ
JPH07242666A (ja) 1994-03-08 1995-09-19 Fujisawa Pharmaceut Co Ltd 複素環化合物
WO1999051587A1 (en) * 1998-04-01 1999-10-14 Ono Pharmaceutical Co., Ltd. Fused thiophene derivatives and drugs containing the same as the active ingredient
US20040009537A1 (en) * 2002-01-11 2004-01-15 Jack Roos Methods of modulating and of identifying agents that modulate intracellular calcium
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
US20060074124A1 (en) * 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
ATE369806T1 (de) 2004-08-18 2007-09-15 Robert Boettcher Einschraubbares enossales dentalimplantat
MX2007007103A (es) 2004-12-13 2008-03-10 Lilly Co Eli Derivados espiro como inhibidores de lipoxigenasa.
AP2008004432A0 (en) 2005-10-07 2008-04-30 Glenmark Pharmaceuticals Sa Substituted benzofused derivatives and their use as vanilloid receptor ligands
JP2009542608A (ja) 2006-06-29 2009-12-03 アステックス・セラピューティクス・リミテッド 医薬組合せ剤
JP5523829B2 (ja) 2006-06-29 2014-06-18 アステックス、セラピューティックス、リミテッド 複合薬剤
EP2049548A1 (en) 2006-07-27 2009-04-22 UCB Pharma, S.A. Fused oxazoles & thiazoles as histamine h3- receptor ligands
WO2008033564A1 (en) 2006-09-15 2008-03-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
JP5329444B2 (ja) 2007-03-19 2013-10-30 アストラゼネカ・アクチエボラーグ Ｔｏｌｌ様受容体（ｔｌｒ７）モジュレーターとしての９−置換−８−オキソ−アデニン化合物
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02104578A (ja) * 1988-08-25 1990-04-17 Fujisawa Pharmaceut Co Ltd ベンズアゾール誘導体、その製造法およびそれを含有する医薬組成物
JP2009514954A (ja) * 2005-11-04 2009-04-09 ハイドラ バイオサイエンシズ インコーポレイテッド Ｔｒｐｖ３機能を変調するための化合物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020502089A (ja) * 2016-12-09 2020-01-23 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 化合物、組成物および方法
JP2022153568A (ja) * 2016-12-09 2022-10-12 デナリ セラピューティクス インコーポレイテッド 化合物、組成物および方法
US12180211B2 (en) 2016-12-09 2024-12-31 Denali Therapeutics Inc. Compounds, compositions and methods

Also Published As

Publication number Publication date
AU2009329192A1 (en) 2011-12-01
EP2367825A1 (en) 2011-09-28
GEP20146099B (en) 2014-05-27
WO2010070452A1 (en) 2010-06-24
AU2009329192A2 (en) 2012-03-29
TW201022283A (en) 2010-06-16
US20100152192A1 (en) 2010-06-17
AR076830A1 (es) 2011-07-13
MX2011006132A (es) 2011-09-01
CA2746077A1 (en) 2010-06-24
NZ595777A (en) 2013-07-26
US8318928B2 (en) 2012-11-27
EA201190004A1 (ru) 2012-11-30

Similar Documents

Publication Publication Date Title
US8318928B2 (en) Fused imidazole carboxamides as TRPV3 modulators
JP2012512151A5 (cg-RX-API-DMAC7.html)
JP5461525B2 (ja) Ｔｒｐｖ３モジュレーターとしての縮合ピリミジノン化合物
JP6181166B2 (ja) ある種の２−（ピリジン−３−イル）チアゾール類の製造方法
TW200808775A (en) Fused phenyl amido heterocyclic compounds
WO2010109329A1 (en) Furopyrimidinedione derivatives as trpa1 modulators
EP2411397A1 (en) Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
JPH07267964A (ja) 新規ｎ−ヘテロ環状チエノチアジンカルボキシアミド、その製造方法及びその使用方法
WO2013107283A1 (en) Benzoheterocyclic compounds and use thereof
CA3198024A1 (en) Dichlorophenol hsd17b13 inhibitors and uses thereof
JP2012514577A (ja) Ｔｒｐｖ３アンタゴニストとしての縮合イミダゾール誘導体
EP2081894A1 (en) 1h-indole-2-carboxylic acid derivatives useful as ppar modulators
JP2025520081A (ja) Ｔｒｐｍ３媒介性障害を治療するためのインドリジン誘導体
JP2012508790A (ja) Ｔｒｐｖ３アンタゴニストとしてのクロメノン誘導体
JP2012508790A5 (cg-RX-API-DMAC7.html)
KR20130042189A (ko) Ｔｒｐｖ3 조절제로서의 융합 이미다졸 카르복스아미드
AU2023275930A1 (en) New derivatives for treating trpm3 mediated disorders
TW201326148A (zh) 做為ｔｒｐｖ３拮抗劑的色烯酮衍生物
CN103159726A (zh) 作为trpv3拮抗剂的色烯酮衍生物
TW201329089A (zh) 做為ｔｒｐｖ３調節劑的稠合嘧啶酮化合物
TW201331193A (zh) 做為ｔｒｐｖ３拮抗劑的稠合咪唑衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121217

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7421

Effective date: 20130726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140408

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140909